Brind.
  1. Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.

Edwards Lifesciences updated guidelines on August 29, 2025, simplifying care pathways and showing EVOQUE's superior clinical benefit.

1 report, 1 independent Updated Aug 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Edwards Lifesciences updated guidelines on August 29, 2025, simplifying care pathways and showing EVOQUE's superior clinical benefit.

Who's involved

What this event is mainly about
Edwards Lifesciences

Keep exploring

Part of

Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireUpdated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care MADRID, August 29, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for